Articles – Investor Consensus

T2 Biosystems, Inc. (NASDAQ: TTOO) Hails CDC's Commitment to Battle Sepsis in U.S. Hospitals

T2 Biosystems, Inc., a renowned leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, has expressed its appreciation for the U.S. Centers for Disease Control and Prevention (CDC)'s recent efforts to enhance hospital sepsis programs across the United States.

To explore the insights and perspectives Wall Street has on T2 Biosystems, Inc. (NASDAQ: TTOO) and its efforts in sepsis detection and treatment, click here: https://investorconsensus.com/stock-ticker?symbol=TTOO

CDC's Hospital Sepsis Program Core Elements

The CDC has introduced the Hospital Sepsis Program Core Elements to facilitate the implementation, monitoring, and optimization of sepsis programs in hospitals, with the ultimate goal of improving survival rates. This comprehensive program comprises seven key elements: Hospital Leadership Commitment, Accountability, Multi-Professional Expertise, Action, Tracking, Reporting, and Education.

Sepsis is a formidable adversary, claiming far too many lives within hospital walls. Shockingly, one in three individuals who succumb to hospitalization does so with sepsis as a contributing factor. Rapid diagnosis and prompt, appropriate treatment, including the timely administration of antibiotics, are critical for saving lives. However, the challenges related to sepsis awareness and recognition are substantial, as emphasized by Mandy Cohen, M.D., M.P.H., CDC Director, during the announcement of the Hospital Sepsis Program Core Elements. Dr. Cohen emphasized that the CDC is calling upon all U.S. hospitals to establish sepsis programs and elevate the standard of sepsis care by implementing these seven core elements.

T2 Biosystems' Role in Sepsis Detection

T2 Biosystems, Inc. (NASDAQ: TTOO) offers a suite of products, including the T2Dx Instrument, the T2Bacteria Panel, and the T2Candida Panel, which are FDA-cleared and capable of detecting sepsis-causing pathogens directly from whole blood within 3-5 hours. This approach eliminates the need to wait for days for a positive blood culture, a method known for its limitations, such as poor sensitivity and prolonged time to results.

A meta-analysis of 14 controlled studies, published in a peer-reviewed medical journal, compared the use of T2 Biosystems' products to traditional blood culture-based protocols. The results were remarkable: T2 Biosystems' products identified sepsis-causing pathogens 77 hours faster, enabled patients to receive targeted antimicrobial treatment 42 hours faster, allowed clinicians to de-escalate from empiric therapy 7 hours sooner, and reduced hospital and ICU stays by approximately 5 days.

Addressing the Urgency of Sepsis

Data reveals that empiric protocols for administering antimicrobials are only optimal in 30-60% of cases, and each hour of delayed targeted antimicrobial treatment increases mortality risk by up to 8%. Rapid detection of sepsis-causing pathogens is essential for achieving faster targeted antimicrobial therapy, improving antibiotic stewardship, and mitigating the threat of antimicrobial resistance (AMR).

John Sperzel, Chairman and CEO of T2 Biosystems, Inc. (NASDAQ: TTOO), commended the CDC and Dr. Mandy Cohen for their proactive steps in addressing the sepsis crisis affecting U.S. hospitals. Sperzel emphasized the need to move away from outdated technologies and processes that are failing patients, healthcare payors, and providers. He believes that the CDC's leadership will act as a catalyst, accelerating the adoption of innovative products and technologies capable of enhancing the standard of care, reducing costs, and ultimately improving patient outcomes.

Sepsis ranks as the leading cause of death in U.S. hospitals, claiming the lives of approximately 350,000 Americans annually, including 80,000 following hospice discharges. It also represents the highest cost of hospitalization in the U.S., with an annual burden of $62 billion on the healthcare system. Furthermore, sepsis contributes significantly to 30-day re-hospitalization rates, with 19% of sepsis survivors re-hospitalized within 30 days and 40% within 90 days.

T2 Biosystems is at the forefront of rapid sepsis detection, aiming to improve patient care while reducing healthcare costs. The company's product lineup includes the T2Dx Instrument, T2Bacteria Panel, T2Candida Panel, T2Resistance Panel, and T2SARS-CoV-2 Panel, all powered by the proprietary T2 Magnetic Resonance (T2MR) technology. T2 Biosystems also maintains an active pipeline of future products, including the T2Biothreat Panel, T2Cauris Panel, and T2Lyme Panel, along with next-generation solutions for detecting bacterial and fungal pathogens and associated antimicrobial resistance markers.